Pharvaris N.V.

NasdaqGS:PHVS Stock Report

Market Cap: US$1.3b

Pharvaris Valuation

Is PHVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PHVS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PHVS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHVS?

Key metric: As PHVS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PHVS. This is calculated by dividing PHVS's market cap by their current book value.
What is PHVS's PB Ratio?
PB Ratio4.2x
Book€296.79m
Market Cap€1.23b

Price to Book Ratio vs Peers

How does PHVS's PB Ratio compare to its peers?

The above table shows the PB ratio for PHVS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.8x
AVDL Avadel Pharmaceuticals
14.4x64.2%US$1.1b
TLRY Tilray Brands
0.4x72.0%US$1.3b
ANIP ANI Pharmaceuticals
2.8x57.0%US$1.1b
INVA Innoviva
1.8xn/aUS$1.2b
PHVS Pharvaris
4.2x10.1%US$1.3b

Price-To-Book vs Peers: PHVS is good value based on its Price-To-Book Ratio (4.2x) compared to the peer average (7.2x).

Price to Book Ratio vs Industry

How does PHVS's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.02m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.86m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.93m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.45m
PHVS 4.2xIndustry Avg. 1.7xNo. of Companies29PB01.22.43.64.86+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PHVS is expensive based on its Price-To-Book Ratio (4.2x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is PHVS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHVS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PHVS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PHVS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.17
US$34.70
+43.6%
30.8%US$47.30US$13.91n/a7
Nov ’25US$24.15
US$34.69
+43.7%
31.1%US$48.67US$13.74n/a7
Oct ’25US$18.43
US$35.59
+93.1%
31.4%US$50.36US$14.22n/a7
Sep ’25US$18.00
US$32.89
+82.7%
32.5%US$49.98US$14.04n/a6
Aug ’25US$15.94
US$33.50
+110.2%
32.2%US$49.38US$12.97n/a6
Jul ’25US$18.69
US$33.50
+79.2%
32.2%US$50.04US$13.14n/a6
Jun ’25US$18.96
US$33.56
+77.0%
32.5%US$50.50US$13.13n/a6
May ’25US$24.57
US$32.97
+34.2%
32.7%US$49.59US$12.68n/a6
Apr ’25US$21.64
US$34.04
+57.3%
31.3%US$48.98US$12.97n/a6
Mar ’25US$24.16
US$34.19
+41.5%
31.2%US$49.01US$12.95n/a6
Feb ’25US$29.95
US$31.54
+5.3%
37.3%US$48.97US$12.99n/a7
Jan ’25US$28.05
US$29.95
+6.8%
35.4%US$40.68US$11.19n/a7
Dec ’24US$18.59
US$22.22
+19.5%
32.6%US$32.07US$8.14n/a7
Nov ’24US$16.91
US$22.48
+33.0%
34.5%US$33.33US$7.82US$24.157
Oct ’24US$20.87
US$22.07
+5.7%
34.5%US$33.10US$7.76US$18.437
Sep ’24US$21.32
US$21.81
+2.3%
37.3%US$33.98US$7.97US$18.006
Aug ’24US$17.05
US$17.42
+2.1%
38.6%US$26.11US$8.11US$15.946
Jul ’24US$15.14
US$17.41
+15.0%
38.4%US$26.01US$8.07US$18.696
Jun ’24US$9.04
US$15.90
+75.9%
34.8%US$24.03US$7.98US$18.966
May ’24US$9.25
US$16.40
+77.4%
35.1%US$25.15US$8.38US$24.576
Apr ’24US$8.06
US$16.45
+104.2%
36.9%US$24.16US$8.05US$21.646
Mar ’24US$8.29
US$16.45
+98.5%
36.9%US$24.16US$8.05US$24.166
Feb ’24US$9.50
US$17.13
+80.3%
36.6%US$24.78US$8.26US$29.956
Jan ’24US$11.25
US$16.66
+48.1%
35.7%US$23.99US$8.00US$28.056
Dec ’23US$2.09
US$15.29
+631.8%
38.5%US$22.00US$5.14US$18.596
Nov ’23US$4.20
US$16.16
+284.7%
24.0%US$21.30US$10.00US$16.916

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

7D

5.2%

1Y

-4.6%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%